Cipla Ltd. benchmarking: Performance to industry peers

Financial

	Cipla	Dr. Reddy's Lab	Zydus Lifesciences
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	285.0 .	376.0 .	505.0 .
Number of ANDA's Approved By USFDA	230.0 .	301.0 .	428.0 .
Domestic Sales Growth - YoY	7.7 %	11.3 %	12.0 %
US DMF Filings	2472.0 .	n/a	147.0 .
R&D as a % of Total Sales	7.8 %	7.3 %	8.8 %
Financials
5 yr Average ROE	13.9 %	15.68 %	18.47 %
5yr average Equity Multiplier	1.25	1.41	1.52
5yr Average Asset Turnover Ratio	0.78	0.74	0.66
5yr Avg Net Profit Margin	14.31 %	15.18 %	19.02 %
Price to Book	3.29	2.9	3.86
P/E	29.19	26.22	29.37
5yr Avg Cash Conversion Cycle	-4.31 Days	74.48 Days	-84.89 Days
Inventory Days	57.83 Days	76.14 Days	36.38 Days
Days Receivable	50.64 Days	95.44 Days	36.93 Days
Days Payable	105.99 Days	102.6 Days	160.15 Days
5yr Average Interest Coverage Ratio	53.73	35.66	30.19
5yr Avg ROCE	19.36 %	21.82 %	19.65 %
5yr Avg Operating Profit Margin	23.02 %	23.61 %	24.4 %
5 yr average Debt to Equity	0.03	0.12	0.17
5yr CAGR Net Profit	17.0 %	23.71 %	16.23 %
5yr Average Return on Assets	11.19 %	11.24 %	12.22 %
Shareholdings
Promoter Holding	29.21 %	26.63 %	75.0 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-4.34 %	-0.07 %	0.02 %
Change in Mutual Fund Holding (3 Yrs)	3.66 %	3.32 %	-0.71 %

Business

	Cipla	Dr. Reddy's Lab	Zydus Lifesciences
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 94.65 New ventures 5.35 Proprietary Products 0 Global Generics 0 0 IM Formulations 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 API 0 Wellness 0 Animal Health 0 India Formulations 0 US Formulations 0	Product Wise Break-Up Wellness 0 India Formulations 0 Alliances 0 New ventures 0 US Formulations 0 API 0 Formulations 89.21 Proprietary 0.17 Pharmaceutical 0 Animal Health 0 Emerging Markets 0 IM Formulations 0 Europe Formulatios 0 Pharmaceutical 10.62	Product Wise Break-Up Wellness 14.0 India Formulations 25.0 Alliance 0.1 New ventures 0 US Formulations 41.0 Active Pharmaceutical Ingredient (API) 3.0 Global Generics 0 Proprietary Products 0 Pharmaceutical 0 Animal Health 0 Emerging Markets 0 EMB Formulations 12.0 Europe Formulatios 0 0 Others 4.9
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 36.4 Anti-Infective 13.8 Cardiac Science 11.8 Gastro Intestinal 5.5 Anti - Diabetes 5.5 Urology 5.1 Central Nervous System (CNS) 4.5 Pain Management 4.3 Derma 3.5 Ophthalmology 2.6 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 7.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 49.0 North America 21.0 SAGA 14.0 Europe 13.0 Global API 2.0 Rest of the World 0 Emerging Markets 0 Russia 0 USA 0 Others 1.0	Location Wise Break-Up Rest of the World 0 Russia 7.99 Europe 0 USA 48.56 Global API 0 North America 0 SAGA 0 Emerging Markets 0 India 17.36 Others 26.09	Location Wise Break-Up Rest of the World 0 Russia 0 Europe 0 USA 47.94 Global API 0 North America 0 SAGA 0 Emerging Markets 0 India 39.81 Others 12.25
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 94.86 New Ventures 5.14 Proprietary Products 0 0 Global Generics 0 Consumer Products 0	Operating Profit Break-Up Consumer Products 0 New Ventures 0 Pharmaceuticals 0 Global Generics 97.0 Proprietary Products 0.09 Pharmaceutical Services and Active Ingredients 2.91	Operating Profit Break-Up Consumer Products 0 New Ventures 0 Pharmaceuticals 100.0 Global Generics 0 Proprietary Products 0 0
Asset Break-Up	Asset Break-Up India 49.7 USA 28.99 South Africa 18.03 United States 0 Switzerland 0 Others 3.28	Asset Break-Up South Africa 0 USA 2.37 USA 0 Switzerland 8.45 India 80.24 Others 8.94	Asset Break-Up South Africa 0 United States 0 USA 4.31 Switzerland 0 India 93.18 Others 2.51

Cipla Ltd.

Cipla Ltd.

Financial

Business

SIGN UP FOR FREE